

Pomalidomide ▼

- ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

This patient is on pomalidomide

Information for Patients:

- You **MUST** tell your prescriber immediately if you experience any symptom that causes concern.
- You **MUST** inform your prescriber immediately if you suspect that you or your female partner is pregnant.

Date of preparation of text: February 2024

Approved by MHRA: April 2024

PATH-POM-004_v.2.0

Prescription Details:

Prescription Date	DD/MM/YYYY
Has the patient received counselling?:	Yes <input type="checkbox"/> No <input type="checkbox"/>
Childbearing potential assessment:	WCBP / WNCBP / Male
This patient is receiving pomalidomide for treatment of:	
<input type="checkbox"/> Multiple Myeloma or	
<input type="checkbox"/> Relapsed and Refractory Multiple Myeloma	

Information for Patients and Healthcare Professionals:

Pomalidomide is an immunomodulator and is an expected human teratogen therefore:

- Female patients of childbearing potential must use at least one effective method of contraception and male patients with pregnant partners or partners of childbearing potential not using effective contraception must use condoms (even if man has had a vasectomy)
- Female patients of childbearing potential must have regular pregnancy tests to ensure that they are not pregnant, except in the case of confirmed tubal sterilisation.

Emergency contact information:

Emergency Prescriber Contact:

Telephone Number during office hours:

Telephone number after office hours:

For complete information on the side effects of pomalidomide, patients should read the Package Leaflet and Healthcare professionals should read the Summary of Product Characteristics.

Date of preparation of text: February 2024

Approved by MHRA: April 2024

PATH-POM-004_v.2.0